Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,940,543 papers from all fields of science
Search
Sign In
Create Free Account
onartuzumab
Known as:
Anti-MET Monoclonal Antibody MetMAb
, MetMAb
A humanized monovalent monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met) with potential antineoplastic activity…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (1)
Monoclonal Antibodies
NCIt Antineoplastic Agent Terminology
antigen binding
Narrower (1)
OA-5D5
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Derived neutrophil lymphocyte ratio may predict bene fi t from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies
K. Tanabe
,
M. Fujii
,
+13 authors
M. Takeuchi
2015
Corpus ID: 145034126
Background: The superiority of cisplatin and gemcitabine (CisGem) chemotherapy over gemcitabine (Gem) alone in patients with…
Expand
2015
2015
Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple…
M. Borin
,
Meng Chen
,
+4 authors
M. Stroh
Cancer Chemotherapy and Pharmacology
2015
Corpus ID: 25812575
PurposeThe potential effect of onartuzumab, when administered with or without bevacizumab in combination with weekly paclitaxel…
Expand
2014
2014
FDA approvals for the first 6 months of 2014
Nature reviews. Drug discovery
2014
Corpus ID: 42953688
2013
2013
Abstract P2-16-01: A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally…
V. Diéras
,
D. Yardley
,
+7 authors
S. Mocci
2013
Corpus ID: 71237905
Background: Dysregulation of the hepatocyte growth factor (HGF)/MET pathway has been observed in many malignancies. In patients…
Expand
2013
2013
Abstract C34: Using quantitative image analysis of a putative immunohistochemistry assay against C-met to guide companion diagnostic decisions.
Joseph S. Krueger
,
B. Laffin
,
Mirza Peljto
,
Mahipal V Suraneni
,
H. Lange
,
David Young
2013
Corpus ID: 84696548
When developing an immunohistochemistry (IHC) based biomarker or companion diagnostic assay, establishing reagent specificity is…
Expand
2012
2012
PK/PD Modeling of Anti-Tumor Response in Xenograft Mice Receiving MetMAb, a One-Armed Monoclonal Antibody, in Combination With Tarceva® : 30 Point Master’s Project
Ari Brekkan Viggosson
2012
Corpus ID: 68746813
PK/PD Modeling of Anti-Tumor Response in Xenograft Mice Receiving MetMAb, a One-Armed Monoclonal Antibody, in Combination With…
Expand
2011
2011
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, MetMAb, in patients with advanced solid tumors.
S. Bai
,
Yan-chao Xin
,
+5 authors
Premal Patel
Journal of Clinical Oncology
2011
Corpus ID: 42239595
2571 Background: MetMAb is a recombinant, humanized, monovalent monoclonal antibody directed against the tyrosine kinase Met…
Expand
2011
2011
DR LOVE: Would you discuss the results you presented at ASCO 2011 evaluating MetMAb in combination with erlotinib for advanced NSCLC?
D. Spigel
2011
Corpus ID: 51824066
2010
2010
Phase Ib dose-escalation study of MetMAb, a monovalent antagonist antibody to the receptor MET, in combination with bevacizumab in patients with locally advanced or metastatic solid tumors.
R. Moss
,
J. Bothos
,
+7 authors
Premal H. Patel
2010
Corpus ID: 73092038
e13050 Background: Crosstalk between the Met and vascular endothelial growth factor (VEGF) pathways may be important during…
Expand
2010
2010
NSCLC: MetMAb + Erlotinib Extends Survival in Subset of Lung Cancer Patients
C. Laiño
2010
Corpus ID: 76088460